INT95048

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.51
First Reported 2001
Last Reported 2010
Negated 0
Speculated 4
Reported most in Body
Documents 61
Total Number 66
Disease Relevance 56.01
Pain Relevance 5.62

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
superior 2
row 1
DA neurons 1
faces 1
lobes 1
ADHD1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Dopamine 976 100.00 Very High Very High Very High
Neurotransmitter 72 99.64 Very High Very High Very High
Locus ceruleus 62 99.12 Very High Very High Very High
alcohol 124 98.28 Very High Very High Very High
Opioid 1 97.92 Very High Very High Very High
fluoxetine 23 97.04 Very High Very High Very High
Ventral tegmentum 10 96.28 Very High Very High Very High
depression 254 95.84 Very High Very High Very High
Central nervous system 20 93.68 High High
nMDA receptor 47 93.24 High High
Disease Link Frequency Relevance Heat
Attention Deficit Hyperactivity Disorder 9173 100.00 Very High Very High Very High
Manic Depressive Disorder 619 100.00 Very High Very High Very High
Conduct Disorder 111 100.00 Very High Very High Very High
Lifespan 42 100.00 Very High Very High Very High
Depression 304 99.92 Very High Very High Very High
Epilepsy 29 99.62 Very High Very High Very High
Anxiety 65 98.92 Very High Very High Very High
Convulsion 50 98.92 Very High Very High Very High
Fetal Alcohol Syndrome 2 98.64 Very High Very High Very High
Mental Disorders 314 97.28 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
It is noteworthy that despite the observation that 62% of subjects showed a 30% reduction in ADHD symptoms, the scores on the ADHD rating scales at endpoint continued to be moderately elevated (21.2 ± 10.6) indicative of residual ADHD symptomatology.
Negative_regulation (reduction) of ADHD associated with attention deficit hyperactivity disorder
1) Confidence 0.51 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2515893 Disease Relevance 1.80 Pain Relevance 0
Earlier studies in children and adults demonstrated response rates similar to MPH in ADHD symptom reduction with minimal side effects.31,42 Despite comparable efficacy, there is some indication of bias in atomoxetine prescription practices.
Negative_regulation (reduction) of ADHD associated with attention deficit hyperactivity disorder
2) Confidence 0.46 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2732009 Disease Relevance 0.89 Pain Relevance 0.06
In this dataset, 55% of those with ADHD in the Primary Sample and 76% of the Alternative Sample (ADHD but not bipolar) showed a 30% reduction in ADHD symptom severity.
Negative_regulation (reduction) of ADHD associated with attention deficit hyperactivity disorder
3) Confidence 0.44 Published 2010 Journal BMC Psychiatry Section Body Doc Link PMC2954995 Disease Relevance 0.48 Pain Relevance 0
For those with both ADHD and PBD (sub-sample in row 3), the mean decrease in bipolar symptoms was 43% (t(28) = 3.9, p < .001, ES = 0.72), and the mean decrease in ADHD symptoms was 40% (t(28) = 2.9, p < .002, ES = .62).
Negative_regulation (decrease) of ADHD in row associated with manic depressive disorder and attention deficit hyperactivity disorder
4) Confidence 0.44 Published 2010 Journal BMC Psychiatry Section Body Doc Link PMC2954995 Disease Relevance 0.81 Pain Relevance 0
Finally, for those with only ADHD but not bipolar, the mean decrease in ADHD symptoms was 47% (t(40) = 6.9(40), p < .001, ES = 1.04).
Negative_regulation (decrease) of ADHD associated with attention deficit hyperactivity disorder
5) Confidence 0.44 Published 2010 Journal BMC Psychiatry Section Body Doc Link PMC2954995 Disease Relevance 0.78 Pain Relevance 0
The use of a 30% reduction in ADHD symptoms is more conservative than recent trials (25% reduction; [26]) and commensurate with previous work [17,28,29].
Negative_regulation (reduction) of ADHD associated with attention deficit hyperactivity disorder
6) Confidence 0.41 Published 2008 Journal Behav Brain Funct Section Body Doc Link PMC2442604 Disease Relevance 0.10 Pain Relevance 0
For all randomized patients, the mean baseline DSM-IV ADHD-RS total score (37.0 on a scale of 0 to 54) indicated moderate to marked severity of ADHD symptomatology.
Negative_regulation (severity) of ADHD associated with attention deficit hyperactivity disorder
7) Confidence 0.41 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697545 Disease Relevance 0.73 Pain Relevance 0
The results indicated that both drugs significantly reduced ADHD symptoms on the DSM-IV Adult Behavior Checklist for Adults over placebo (p < 0.05).
Negative_regulation (reduced) of ADHD associated with attention deficit hyperactivity disorder
8) Confidence 0.41 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697545 Disease Relevance 0.88 Pain Relevance 0.03
6.8 ± 5.0, p < 0.05) ADHD symptoms were significantly improved with risperidone, improvement was modest, and only 29% of subjects (N = 6) showed a 30% reduction in ADHD rating scale scores and had a CGI-I ?
Negative_regulation (reduction) of ADHD associated with attention deficit hyperactivity disorder
9) Confidence 0.37 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Abstract Doc Link PMC2515893 Disease Relevance 1.10 Pain Relevance 0
Although 62% of mania responders showed a 30% reduction in ADHD-RS scores, only 35% were rated as much or very much improved on the ADHD specific CGI-I ratings and 29% were rated as responders (CGI ?
Negative_regulation (reduction) of ADHD-RS associated with manic depressive disorder and attention deficit hyperactivity disorder
10) Confidence 0.37 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2515893 Disease Relevance 1.38 Pain Relevance 0.08
At five months, both brief and extended groups reported a reduction in child sleep problems and ADHD symptoms (both 67%).
Negative_regulation (reduction) of ADHD associated with attention deficit hyperactivity disorder
11) Confidence 0.37 Published 2010 Journal BMC Pediatr Section Body Doc Link PMC3022790 Disease Relevance 0.78 Pain Relevance 0
The lifetime persistence of symptoms and impairment of ADHD is the hallmark of this disorder in the majority of cases.
Negative_regulation (impairment) of ADHD associated with attention deficit hyperactivity disorder
12) Confidence 0.37 Published 2010 Journal BMC Psychiatry Section Body Doc Link PMC2942810 Disease Relevance 0.72 Pain Relevance 0
If we could effectively manage sleep problems in children with ADHD then we may be able to improve child ADHD symptoms, quality of life and school attendance, as well as parent mental health and work attendance.
Negative_regulation (improve) of ADHD associated with mental disorders and attention deficit hyperactivity disorder
13) Confidence 0.37 Published 2010 Journal BMC Pediatr Section Body Doc Link PMC3022790 Disease Relevance 1.11 Pain Relevance 0.21
The primary efficacy measure was the proportion of ADHD responders, defined as at least a 30% reduction in the investigator-rated ADHD-RS, at week 8.
Spec (investigator) Negative_regulation (reduction) of ADHD-RS associated with attention deficit hyperactivity disorder
14) Confidence 0.36 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697545 Disease Relevance 0.44 Pain Relevance 0.10
Therefore, it has been difficult to estimate the rate of persistence of ADHD from childhood into adulthood, as prospective studies have produced mixed results.7,8
Negative_regulation (persistence) of ADHD associated with attention deficit hyperactivity disorder
15) Confidence 0.36 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697545 Disease Relevance 1.64 Pain Relevance 0.03
The primary efficacy measure was the proportion of ADHD responders, defined as at least a 30% reduction in the investigator-rated ADHD-RS, at week 8.
Spec (investigator) Negative_regulation (reduction) of ADHD associated with attention deficit hyperactivity disorder
16) Confidence 0.36 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697545 Disease Relevance 0.44 Pain Relevance 0.10
As expected, the results indicated that ATX was clinically effective in reducing the overall ADHD symptoms, as measured by the CAARS.
Negative_regulation (reducing) of ADHD associated with attention deficit hyperactivity disorder
17) Confidence 0.36 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697545 Disease Relevance 0.41 Pain Relevance 0
ADHD increases seizure risk, while patients with epilepsy have an increased prevalence of ADHD.
Negative_regulation (prevalence) of ADHD associated with epilepsy, convulsion and attention deficit hyperactivity disorder
18) Confidence 0.34 Published 2009 Journal Expert Rev Neurother Section Abstract Doc Link 19951134 Disease Relevance 1.17 Pain Relevance 0.06
CONCLUSIONS: Although this was a brief pilot study with a small sample size, in this cohort, APZ led to clinical benefit in reducing ADHD symptoms and improving overall functioning.
Negative_regulation (reducing) of ADHD
19) Confidence 0.34 Published 2008 Journal J Child Adolesc Psychopharmacol Section Body Doc Link 18759644 Disease Relevance 0.11 Pain Relevance 0
ADHD versus ADHD + conduct disorder
Negative_regulation (disorder) of ADHD associated with conduct disorder and attention deficit hyperactivity disorder
20) Confidence 0.34 Published 2005 Journal Theor Biol Med Model Section Body Doc Link PMC1352384 Disease Relevance 0.93 Pain Relevance 0.11

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox